for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evoke Pharma Inc

EVOK.OQ

Latest Trade

1.43USD

Change

0.03(+2.14%)

Volume

51,617

Today's Range

1.38

 - 

1.49

52 Week Range

1.09

 - 

6.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.40
Open
1.42
Volume
51,617
3M AVG Volume
8.66
Today's High
1.49
Today's Low
1.38
52 Week High
6.05
52 Week Low
1.09
Shares Out (MIL)
32.37
Market Cap (MIL)
45.32
Forward P/E
-4.12
Dividend (Yield %)
--

Next Event

Q2 2021 Evoke Pharma Inc Earnings Release

Latest Developments

More

Evoke Pharma Reports First Quarter 2021 Financial Results

Evoke Pharma Announces Pricing Of Public Offering Of Common Stock

Evoke Pharma Reports Q3 Loss Per Share $0.08

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evoke Pharma Inc

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Industry

Biotechnology & Drugs

Contact Info

420 Stevens Ave Ste 370

SOLANA BEACH, CA

92075-2081

United States

+1.858.3451494

https://evokepharma.com/

Executive Leadership

Cam L. Garner

Chairman and Co Founder

David A. Gonyer

CEO, Founder, Director

Matthew J D'Onofrio

Executive Vice President, Chief Business Officer Treasurer, Secretary ,

Marilyn R. Carlson

Chief Medical Officer

Todd C. Brady

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.460

2019

-0.320

2020

-0.520

2021(E)

-0.340
Price To Earnings (TTM)
--
Price To Sales (TTM)
399.51
Price To Book (MRQ)
5.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.01
LT Debt To Equity (MRQ)
64.01
Return on Investment (TTM)
-174.97
Return on Equity (TTM)
-116.74

Latest News

Latest News

BRIEF-Evoke Pharma Extends Cash Runway To 2Q 2021

* EVOKE PHARMA INC - AS OF JUNE 30, 2020 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $8.0 MILLION Source text for Eikon: Further company coverage:

BRIEF-Evoke Pharma Says FDA Approves GIMOTI

* EVOKE PHARMA INC - AS OF MAY 31, 2020, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $4.7 MILLION.

BRIEF-Evoke Pharma Reports Q4 Loss Per Share Of $0.06

* EVOKE PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up